2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

2:30PM-4:00PM: Abstract Number: 1992

Rheumatoid Arthritis Is an Independent Risk Factor for Increased Insulin Resistance and Impaired Beta-Cell Function: Impact of Disease Activity

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 1991

Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 2007

Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 1975

Severity and Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1995

Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 2009

The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 1964

The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1993

The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 2015

The Systemic Sclerosis Disease State Is Associated with Specific Alterations in Gastrointestinal Microbiota in Two Independent Cohorts

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 1963

Thrombospondin-1 Is Elevated in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Free Active TGF-b1 Levels, IL-1b and IL-17A

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2006

Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 1976

Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2012

Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 2003

Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 1984

Which Factors Associate with Localized Knee Pain and Generalized Pain: A 10-Year Longitudinal Study?

Pain – Basic and Clinical Aspects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].